Karyopharm cuts 20% of staff, pursues strategic and financing options amid cash crunch

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) - quick read on what's happening inside the company

Bottom line: management is executing cost cuts and advancing Phase 3 programs while simultaneously running short on liquidity and facing heavy debt maturities and covenants. The company has announced Board-led reviews of strategic and financing alternatives (including potential sale or restructuring) and reduced headcount (~20% announced July 11, 2025) to preserve cash.

Key facts & statistics (from Form 10‑Q; amounts in thousands unless otherwise noted)
- Cash and cash equivalents: $38,725 (June 30, 2025).
- Investments (available-for-sale): $12,972 (June 30, 2025).
- Combined cash, cash equivalents and investments (MD&A): $51.7 million as of June 30, 2025.
- Total assets: $104,879 (June 30, 2025) vs $164,418 (Dec 31, 2024).
- Total liabilities: $343,805 (June 30, 2025).
- Total stockholders' deficit: $(238,926) (June 30, 2025).
- Accumulated deficit: $(1,624,174) (June 30, 2025).
- Total revenue (Q2 2025): $37,929 vs $42,786 (Q2 2024).
- Product revenue, net (Q2 2025): $29,681 vs $28,032 (Q2 2024).
- License & other revenue (Q2 2025): $8,248 vs $14,754 (Q2 2024).
- Loss from operations (Q2 2025): $(24,387) vs $(28,120) (Q2 2024).
- Net (loss) income (Q2 2025): $(37,252) vs $23,792 (Q2 2024).
- Basic net (loss) per share (Q2 2025): $(4.32) vs $2.26 (Q2 2024).
- Interest expense (Q2 2025): $11,228 (three months); total other income (expense), net (Q2 2025): $(12,825) vs $51,979 (Q2 2024) (note: Q2 2024 included a $44,702 gain on extinguishment of debt).
- Net cash used in operating activities (six months ended June 30, 2025): $(57,681).
- Net decrease in cash, cash equivalents and restricted cash (six months): $(23,739).
- Convertible senior notes due 2025 outstanding principal: $24,500 (2025 Notes).
- Convertible senior notes due 2029 principal: $116,000 (2029 Notes).
- Senior secured Term Loan principal: $100,000 (Term Loan).
- Deferred royalty obligation carrying value: $73,499 (June 30, 2025).
- Warrants outstanding (May 2024 Warrants): 3.1 million (liability classified); total warrants outstanding as of June 30, 2025: up to 3.7 million shares.
- Covenant note: Company must maintain cash, cash equivalents and investments of at least $25.0 million at all times under credit agreements.

What's happening inside - operational snapshot
- Management is prioritizing runway preservation: announced workforce reductions (about 20% July 11, 2025) and said it will pursue financing and strategic alternatives (equity offerings, debt refinancings, collaborations, possible sale or restructuring).
- Clinical focus continues: Phase 3 myelofibrosis trial patient screening expected to close August 2025 and top-line data expected March 2026 (company statement). Investment is being concentrated on selinexor late‑stage programs (myelofibrosis, endometrial cancer, multiple myeloma).
- Cash management measures include a previously completed refinancing (May 2024) that created the Term Loan and 2029 Notes but left liquidity and maturity pressure (notably the 2025 Notes maturing Oct 15, 2025 with $24.5M principal outstanding).
- Management remains in compliance with covenants as of June 30, 2025 but acknowledges "substantial doubt" about ability to continue as a going concern beyond one year without further financing.

Positive aspects of the income statement / operations
- Product revenue improvement in Q2 2025: product revenue, net rose to $29.7M (Q2 2025) from $28.0M (Q2 2024), driven by gross‑to‑net favorability (lower 340B discounts).
- Operating expense discipline: R&D and SG&A declined year-over-year for both the quarter and six‑month periods (R&D Q2 2025 $32,788 vs $38,371; SG&A Q2 2025 $28,477 vs $31,070), reflecting cost reductions and headcount cuts.
- Receivables and inventory management: accounts receivable, net $32,932; inventory modest at $4,992 (June 30, 2025), consistent with commercial supply control.
- Ongoing partner support: Menarini reimbursements continue (Menarini revenue Q2 2025 $7,621) and Menarini has reimbursed development-related expenses (subject to limits).

Negative aspects of the income statement / key risks
- Large recurring operating losses: net loss Q2 $(37.3M) and YTD $(60.7M); accumulated deficit $(1.624B).
- Nonrecurring income distorted prior-year results: Q2 2024 included a $44.7M gain on extinguishment of debt that did not recur in 2025, so year-over-year comparisons overstate prior-year profitability.
- Rising financing costs and debt burdens: interest expense rose (three‑month interest expense includes $11.2M), driven by Term Loan and 2029 Notes; significant debt amortization and embedded derivative fair value volatility continue to impact "other income (expense), net."
- Liquidity runway is short and covenant-driven: management states current resources fund operations into October 2025 given the $24.5M 2025 Notes maturity and $25M minimum liquidity covenant; excluding those items runway extends to January 2026 - both horizons are tight and contingent on executing financing or strategic alternatives.
- Stockholders' deficit and potential dilution: total stockholders' deficit $(238,926); outstanding convertible notes and warrants (3.7M warrants, 2029 conversion features) create dilution risk and mark-to-market volatility on liability-classified instruments.
- Going concern disclosure: company explicitly concluded there is "substantial doubt" about ability to continue as a going concern within one year absent additional funding or strategic transactions.

Near-term things to watch
- Liquidity / financing announcements: any equity raise, debt refinancing, sale/merger or royalty monetization transaction - timing and terms will be critical (and potentially dilutive).
- 2025 Notes maturity (Oct 15, 2025): whether these notes are refinanced, repurchased, converted or extended.
- Covenant compliance and minimum liquidity: maintain ≥ $25.0M per Credit Agreement - covenant breaches would be material.
- Clinical milestones: progress and topline timing for Phase 3 myelofibrosis (top line expected March 2026) and continued progress in endometrial cancer and multiple myeloma programs.
- Quarterly cash burn and operating cash flow trends - management guidance and actual cash used in operating activities (six months used $(57.7M)).

Analyst take
- The company has commercial traction (XPOVIO product revenue) and ongoing late‑stage programs that can create value if trials succeed. Operational cost reductions have reduced burn, but substantial debt and contractual royalty obligations plus a short cash runway force near‑term dependence on external financing or strategic deals that may be dilutive or value‑destructive.
- Investors should treat recent comparisons to 2024 with caution because the prior period's gain on extinguishment of debt ($44.7M) materially improved 2024 results and is nonrecurring. The immediate priorities for the company are (1) secure financing or strategic alternative to address the 2025 Notes maturity and covenant requirements and (2) continue execution on the Phase 3 programs that carry the highest value potential.

If you want, I can prepare a short financial model sensitivity (runway vs. financing size / dilution scenarios) and a timeline of clinical and corporate catalysts to watch.